Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous Aug 16 | 2023Abecma’s US Revenue Decreased; FDA Formally Puts DARIC33’s Trial on Hold; Manufacturing Capacity Ramping Up; 2seventy bio Q2 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, Topics Aug 16 | 2023FDA Lifts Clinical Hold on CART-ddBCMA’s Ph2 iMMagine-1 Trial; How Did the Hold Impact CART-ddBCMA Development Timelines? Arcellx’s Q2 2023 Results SummaryAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Aug 14 | 2023GC012F’s US Trial Initiated; GC012F to Be Evaluated in SLE in the US; Pipeline Reprioritization; Gracell’s Q2 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous Aug 10 | 2023Completion of Afami-cel's BLA Submission Delayed; FDA Agrees to Cohort 2 of the SPEARHEAD-1 Trial Acting as Confirmatory Evidence for Full Approval; ADP-A2M4CD8's SURPASS-3 Trial Initiated; Adaptimmune's Q2 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T, CD19 Aug 10 | 2023Caribou to Share FDA’s Feedback on Potential CB-010 Pivotal Trial by YE 2023; Caribou’s Q2 2023 Earnings SummaryAccess Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T, CD19 Aug 09 | 2023Thoughts on Astellas’s Strategic Investment in Poseida; Astellas Gains Rights over P-MUC1C-ALLO1 Program; First Patient in P-CD19CD20-ALLO1 Trial to Be Dosed in Early 2024; Gracell Announces Private InvestmentAccess Free BlastFree
Posted in: Autologous, CAR-T Aug 08 | 2023ARCE Tx to Advance ARD103 into the Clinic after Promising Preclinical Results in AML; NKGen Biotech and Affimed not Proceeding to Ph2 Trial Combining AFM24 and SNK01 in Solid Tumors; ASCO Breakthrough 2023 AnalysisAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD19, CD22, Dual/triple agonist Aug 07 | 2023Cellectis to Provide Updates of All Clinical Programs in 2023; Company to Advance FAP-Targeting UCART Program in Solid Tumors into the Clinic; Precision Actively Seeking Partners to Advance Azer-cel and PBCAR19B; Cellectis’s and Precision’s Q2 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Aug 04 | 2023Yescarta Sales Continue to Increase While Tecartus Revenue Plateaus; Gilead Considers Entry into Autoimmune Diseases; Gilead’s Q2 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD19 Aug 04 | 2023Obe-cel’s BLA Submission on Track for YE 2023; New Obe-cel Ph1 Trial to Start for SLE; Two Assets Added to the Pipeline; Autolus’s Q2 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T, CD19, Topics Aug 03 | 2023ALLO-501A’s ALPHA2 Trial to Start Enrollment Ex-US; EXPAND Continues Recruiting Slowly; ALPHA3 Trial Redefined; Allogene’s Q2 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Aug 02 | 2023Updated Results of BRL-201 in R/R B-NHL; MeiraGTx and CERo Present Innovative Cell Therapy Technologies; ASGCT Spotlight on Immuno-Oncology 2023 AnalysisAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD19 Jul 28 | 2023Precision Receives Feedback from the FDA on Azer-cel’s Registrational PathwayAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19, Topics Jul 28 | 2023Abecma Sales Decrease While Breyanzi Revenue Keeps Growing; Plans to Start a BMS-986393 Registrational Trial; BMS Invests in Immatics; BMS’s Q2 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, Topics Jul 21 | 2023Carvykti's Revenue Increases Over +60% QoQ; JNJ Q2 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19, Topics Jul 18 | 2023Kymriah Sales Continue to Slowly Decrease; No Updates of T-Charge Programs; Novartis’s Q2 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T, CD19, Topics Jul 17 | 2023Caribou Shares Positive Data from ANTLER Trial in B-NHL; Pfizer Invests in Caribou’s BCMA-targeting Cell TherapiesAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, Topics Jul 17 | 2023No Cell Therapy-Related Updates in July’s CHMP AgendaAccess Free BlastFree
Posted in: Allogeneic, CD19 Jul 06 | 2023The FDA Clears Poseida’s P-CD19CD20-ALLO1 IND in B-Cell MalignanciesAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jun 23 | 2023Abecma’s T2V Receives an RSI; When Could Abecma and Carvykti Receive a CHMP Positive Opinion? June CHMP HighlightsAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.